Cumberland Pharmaceuticals Inc. (CPIX)
Valuation Overview•Is Cumberland Pharmaceuticals Inc. Overvalued or Undervalued?
Commands a premium valuation multiple over its peers, likely pricing in superior execution.
Moderate quality score of 48/100, reflecting stable operating margins and manageable leverage.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Average quality business weighed down by significant profitability concerns.
Wall Street sentiment is generally neutral. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
CPIX struggles with subpar profitability and pressured margins. This is backed by a fortress balance sheet, holding significant net cash ($1M) and minimal debt risk.
The company exhibits steady, low-single-digit revenue growth paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-17.2%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $9.1M | +17.6% | +2.0% | +3.5% | +2.9% | |
| EBITDA | -$1.9M | — | — | — | — | |
| Net Income | -$3.1M | +56.2% | +20.1% | — | — | |
| EPS (Diluted) | $-0.22 | +58.7% | — | — | — | |
| Free Cash Flow | $387K | +710.5% | -8.8% | +7.9% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 82.9% | 84.1% | 81.2% | 80.7% |
| Operating Margin | -17.2% | -15.8% | -16.5% | -15.9% |
| Net Margin | -17.2% | -13.1% | -12.5% | -12.1% |
| FCF Margin | 3.2% | 7.7% | 11.0% | 5.9% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.13 | $-0.13 | +0.0% | ||
| Q1'26 | $-0.13 | $-0.01 | +92.3% | ||
| Q4'25 | — | $-0.06 | — | ||
| Q3'25 | — | $0.02 | — | ||
| Q2'25 | — | $0.16 | — | ||
| Q1'25 | — | $-0.02 | — | ||
| Q4'24 | — | $-0.02 | — | ||
| Q3'24 | — | $0.01 | — |
Total return is +6.7% (1Y), lagging the benchmark by -18.3%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +43.7% | +34.4% | — |
| 1Y | +6.7% | -18.3% | — |
| 3YCAGR | +52.9% | +32.4% | — |
| 5YCAGR | +13.9% | +0.7% | — |
| 10YCAGR | +2.2% | -11.6% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Cumberland Pharmaceuticals Inc. (CPIX) valuation, health, and returns.
Based on peer relative multiples, Cumberland Pharmaceuticals Inc. appears Slightly expensive versus peers compared to industry peers.
Cumberland Pharmaceuticals Inc. has multiple valuation anchors: Peer Relative Fair Value: $4.79. A convergence of these signals offers higher conviction.
Cumberland Pharmaceuticals Inc. displays fair financial health with a composite quality score of 48/100, supported by a Altman Z-Score of 0.7 (distress zone), Piotroski F-Score of 6/9, Return on Invested Capital (ROIC) of -8.6%.
Cumberland Pharmaceuticals Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Cumberland Pharmaceuticals Inc.'s current growth trajectory is Accelerating. The company achieved +17.6% 1Y revenue growth and +58.7% 1Y EPS growth, compared to its 3Y revenue CAGR of +2.0%.
Wall Street consensus is Hold based on 0 analysts, beating EPS expectations in 58% of recent quarters with a -1-quarter streak. The consensus price target represents a N/A change from current levels.
Investment risks for Cumberland Pharmaceuticals Inc. include: -56.3% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 0.64x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.